The European Medicines Agency has recommended Fruzaqla, Truqap, and Eribulin Baxter for use in the treatment of specific colorectal and breast cancers.
Data suggest that intermediate clinical endpoints can serve as surrogate endpoints for overall survival in patients with early-stage breast cancer receiving adjuvant therapy.